TUCSON, Ariz., July 23, 2015 /PRNewswire/ -- Cancer Prevention
Pharmaceuticals, Inc. (CPP) today announced that Jon S. Saxe has joined its Board of
Directors.
Saxe brings to CPP many years of experience from the
biotechnology, pharmaceutical and venture capital industries.
He has served as a director of more than 25 companies and currently
is a director of several biotechnology companies, including:
SciClone Pharmaceuticals (NASDAQ: SCLN), where he is chairman;
DURECT Corporation (NASDAQ: DRRX); as well as a number of private
companies. He was president of PDL BioPharma (formerly Protein
Design Labs), and also was president and CEO of Synergen, a
biotechnology company purchased by Amgen.
Prior to his work at biotech companies Saxe was vice president
of licensing and corporate development and head of patent law for
Hoffmann-LaRoche Inc., where he worked for 29 years.
Saxe received a B.S.ChE from
Carnegie Mellon University, a J.D. from
George Washington University School of
Law, and a LL.M. from New York University
School of Law.
"We are honored and excited to have Jon
Saxe join our board," said Jeff
Jacob, chairman of CPP's Board of Directors. "His
broad knowledge of the industry and years of experience both as an
executive and in corporate governance will serve CPP well as it
continues to grow in the coming years. The other members of
the board and I are very much looking forward to working with
Jon."
About Cancer Prevention Pharmaceuticals, Inc. (CPP)
CPP is developing therapeutics that reduce the risk of
cancer. CPP's approach has been used with great success in
other disease categories such as cardiovascular, neurovascular and
infectious disease. Agents that target pre-disease states
have helped reduce death rates from these conditions by 50%-70%
over the past 30 years. Just as these other prevention
therapies represent the largest-selling drug classes on the market
today, CPP believes there is even more potential for therapies that
reduce the risk of cancer. CPP is sponsoring a large Phase
III trial in colon cancer survivors and a Phase III trial for
Familial Adenomatous Polyposis (FAP), an orphan disease that causes
hundreds-to-thousands of colon polyps and has a 100% risk of colon
cancer unless treated by surgical removal of the colon/rectum.
CPP is also working collaboratively with non-profit groups to
support clinical trials in the childhood cancer neuroblastoma, for
the prevention of relapse. Additional information on CPP is
available at www.canprevent.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cancer-prevention-pharmaceuticals-inc-announces-appointment-of-jon-s-saxe-to-its-board-of-directors-300117647.html
SOURCE Cancer Prevention Pharmaceuticals, Inc.